Navigation Links
Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
Date:7/22/2008

Report Includes an Individual's Genetic Risk Based on Clinical Data,

Preventive Measure Guidance and Scientific Educational Materials

WALTHAM, Mass., July 22 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced the launch of an enhanced test report format and information package for the company's Heart Health Genetic Test. The test is currently marketed under the brand name Gensona(R) Heart Health Genetic Test by Quixtar/Amway. The new report will include quantified risk information on heart attack and coronary artery disease generated from clinical studies and conducted by the company. The company believes that this enhanced report format will provide individuals and their physicians more complete information about a person's inflammation-based genetic risk factor for a heart attack. The new package also provides information on the science behind the genetic test and information to help people understand preventive measures and actions that can be taken to lower the risk of heart disease.

In addition, the company will conduct scientific lectures on the Gensona(R) test for interested Quixtar/Amway individual business owners at their scheduled conferences. The first of these lectures will be on Saturday morning and afternoon, July 26, 2008 at the Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel & Convention Center in Valley Forge, PA. Thousands of attendees are expected at the conference.

Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, "Heart disease is by far the leading killer of Americans. Individuals with different interleukin gene variations have vastly different clinical trajectories for heart disease progression. The ability
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
5. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
6. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
7. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
8. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
9. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
10. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
11. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...N, Del., Dec. 3 ParagonRx, a Delaw...isk management and optimal medication use, will ho...,s draft guidance on REMS - Risk Evaluation Mitiga...REMS lifecycle management. Dr. Gary Slatko, chief...S and risk management programs, will lead the one-...
(Date:12/3/2009)...., Dec. 3 In response t...ormation technologies in the evolving healthcare d... Center for Health Informatics (DCHI) to provide a...ersee an innovative interdisciplinary approach to ...ysicians, nurses and healthcare administrators wit...
(Date:12/3/2009)...E, Tenn., Dec. 3 Cumber...ced today that data from a recent clinical trial f...avenous treatment for pain and fever, will be pres...m Pharmacists (ASHP) Midyear Clinical Meeting in L... will be displayed in a poster presentation on Mon...
Breaking Medicine Technology:Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting 2New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting 3JNCI news brief 3A Antibody linked to chemotherapy drug inhibits ovarian cancer in lab 53165 1Its Still Too Early to Be Popping Champagne Corks Expert to Comment on Health Care Reform House Healthcare Proposal 53160 1Its Still Too Early to Be Popping Champagne Corks Expert to Comment on Health Care Reform House Healthcare Proposal 53160 2Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference 53155 1Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference 53155 2
...Data Presented at Leading Influenza Conference , H...sed,pre-clinical data showing how a new flu vaccin... of influenza, including pandemic and,annual, was ...or,the Control of Influenza VI (Options) Conferenc... which will be published in the,European Journal o...
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
Other Medicine Technology:New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6
(Date:12/4/2009)... Vaccinated children less likely to get herpes zos...4 (HealthDay News) -- Children who are vaccinated ...tion against shingles, new findings suggest. , ...72,163 children in southern California who were va...between 2002 and 2008. , Over an average of 2.5...
(Date:12/4/2009)..., , BOSTON and HOUSTON, Dec. 4 /P...#901-- Cyberonics, Inc . (Nasdaq: CYBX ) announc...py , the only FDA-approved implantable medical dev... be featured in 14 presentations at the American ...lace December 4-8 at the Hynes Convention Center i...
(Date:12/4/2009)..., Plantar fasciitis heel ... Stated each year, and cold therapy has been cited... an effective treatment option. In response to th...lection of compressive cold therapy systems for pl...ine of combination night splint therapies. , ...
(Date:12/3/2009)..., Chiropractic Traffic ha...giving away a very popular marketing tool. $1 gets...ng on steriods. Chiropractic Traffic is even incl...ost. , (PRWEB) December 3... a brand new Email marketing tool. Chiropractic M...
(Date:12/3/2009)..., , MINNEAPOLIS, Dec. 3 ...been named a recipient of the 2009 Leapfrog Top Ho...nized for delivering care that is among the best i...ls of efficiency. ,, The Leapfrog survey is the...key issues including mortality rates for common pr...
Breaking Medicine News(10 mins):Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:Orthotics And Beyond Introduces Compressive Cold Therapy Products for Plantar Fasciitis Treatment 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:Children's Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 2
...TISTS WILL CONVENE TO SHARE CUTTING,EDGE RESEARCH ...OWN, W.Va., Aug. 26 On October 16th,2008, the new...Institute,(BRNI) located on the campus on West Vir... research on Alzheimer,s disease,and other memory ...
...xplain what causes the baggy lower eyelids that co... that fat expansion in the eye socket is the prima...xcision should be a component of treatment for pat...tive Surgery , is the first to examine the anatomy...
...ew provided information on the top traumatic brain...e United States as the International Brain Injury ... currently living with the condition. Researchers ...WEB) August 26, 2008 -- LegalView, the most compre...
...Information Offers Single Authoritative, Source o...to Indonesia,s Generics and AP...hua-PRNewswire/ -- Indonesia,s generics,and API (A...s of Thomson Reuters, the world,s leading source o...
...Newswire-FirstCall/ -- Mindray,Medical Internation...facturer,and marketer of medical devices in China,...s converted from Chinese Renminbi to U.S. Dollars....ly, Mindray has issued these historical financial ...
...lly ill rodents with type 1 diabetes have been res...substance other than insulin by scientists at UT S...y of insulin in 1922, type 1 diabetes (insulin-dep...estern researchers, which appear online and in a f...
Other Medicine News:Health News:Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders 2Health News:Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders 3Health News:Why do eyelids sag with age? UCLA study answers mystery 2Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 2Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 3Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 4Health News:Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters 2Health News:Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters 3Health News:Mindray Releases Historical Financial Results Converted into US Dollar Terms 2Health News:UT Southwestern scientists discover leptin can also aid type 1 diabetics 2Health News:UT Southwestern scientists discover leptin can also aid type 1 diabetics 3
...ghly effective surgical alternative for the treatm...s positioned close to the high pressure zone of th...ree support of the urethra in the correct position...es, with minimal tissue dissection. Clinical studi...
...s, the PeaceKeeper 20 gauge multi-modality intraoc...Field comprehensive family of lightweight Eraser b... Combining highly effective bipolar hemostasis wit... in a single use, sterile instrument, the PeaceKee...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
SUR-FIT Natura® Urostomy Pouch
Medicine Products: